期刊
CURRENT PROTEIN & PEPTIDE SCIENCE
卷 19, 期 10, 页码 958-971出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389203718666170828123449
关键词
Immunogenicity; biosensor; peptide; biological drugs; anti-drugs antibodies; ADAs
资金
- Colombia Science, Technology and Innovation Department (Colciencias) [123071150104]
- Universidad de La Sabana
Currently it is well known that all biological drugs, including those with a fully human structure, are capable of inducing a host immune response known as immunogenicity [1]. The presence of ADAs can condition the drug's level and action, thus modifying the therapeutic effect and even the safety profile by its mechanism of action - neutralizing or non-neutralizing - and / or an increase in its clearance. Immunogenicity is a dynamic factor to be taken into account in biological therapy, especially in long-term treatments, and as a relevant aspect in the assessment of secondary response loss [2]. With the above, not only the knowledge but also the management of the immunogenicity of the different biological treatments, represent a useful instrument for optimization of the strategies of use for each drug, and in the design of predictive models of response, which finally permits a significant improvement in the efficacy and safety profile, aiming to a personalization of the therapies, especially in patients with autoimmune diseases, genetic disorders and cancer [3]. This review summarizes the events of immunogenicity that produce the biological drug, the factor that influence to immunogenicity and the assessment of immunogenicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据